Screener
Harrow HROW Branded — Research And Development Expense
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Harrow in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Harrow’s 10-Q, filed May 11, 2026.
- Filed
- May 11, 2026, 4:31 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001493152-26-022254
| Line item | Branded | Compounding | Consolidated |
|---|---|---|---|
| Gross profit | 19,750,000 | 7,295,000 | 27,045,000 |
| Operating expenses | |||
| Selling, general and administrative | 25,759,000 | 6,742,000 | 32,501,000 |
| Research and development | 5,621,000 | 210,000 | 5,831,000 |
| Segment contribution | $(11,630,000) | $343,000 | (11,287,000) |
| Corporate | - | - | 10,729,000 |
| Research and development | 64,000 | ||
| Loss from operations | $(22,080,000) |
Item 1. Financial Statements (unaudited) Item
FAQ
- What is Harrow's branded — research and development expense?
- Harrow (HROW) reported branded — research and development expense of $5.62M in Q1 2026.
- How has Harrow's branded — research and development expense changed year-over-year?
- Harrow's branded — research and development expense increased by 182.0% year-over-year, from $1.99M to $5.62M.
- What does branded — research and development expense mean?
- This metric tracks the costs incurred for the discovery, clinical development, and regulatory approval of new or existing branded ophthalmic products. It reflects the company's commitment to innovation and the long-term pipeline development within the branded segment.
Ask your AI about Harrow's branded — research and development expense.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude